Grifols stock advances as US biopharma IPO plan takes shape

Grifols stock gained 3.56% between the home-market close on Friday, November 6, and Friday, November 13, as the Spanish plasma medicines group developed a new capital-allocation option. On Thursday, November 12, Grifols backed a plan to sell a minority stake in its US biopharma business through an initial public offering, according to Pharmaphorum.

IPO plan targets debt reduction

The proposed listing would allow Grifols to raise equity capital while retaining majority ownership of the US operation. Management intends to use the proceeds to help reduce debt, although the eventual effect will depend on the stake sold, valuation, timing and investor demand.

Grifols stock traded at 11.62 euros on Lang & Schwarz at 11:54 CET on Saturday, November 14. The home-market close stood at 11.65 euros on Friday, November 13, compared with 11.25 euros on Friday, November 6. The latter closing price was reported by The Officer.

Biopharma remains the operating driver

The IPO discussion followed third-quarter growth led by Biopharma. Revenue in the division rose 10.3% at constant currency, while group revenue increased 8.4% to 2.04 billion euros and adjusted EBITDA rose 9.8% to 538 million euros. Net leverage under the credit-agreement definition fell to 3.98 times at the end of September.

For investors, the proposed transaction adds a potential funding route to Grifols' operating deleveraging. It does not yet represent completed debt reduction, and the next key variables are the transaction structure, market conditions and any timetable for execution.

Spanish equities remain the broader market context; see Current market reports.

More news and analyses on Grifols stock